Tectonic Therapeutic (TECX) Projected to Post Quarterly Earnings on Thursday

Tectonic Therapeutic (NASDAQ:TECX) is projected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($1.3163) per share for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Tectonic Therapeutic (NASDAQ:TECX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.35) by $0.17. On average, analysts expect Tectonic Therapeutic to post ($5.27) EPS for the current fiscal year and ($5.70) EPS for the next fiscal year.

Tectonic Therapeutic Trading Down 4.0%

TECX stock opened at $18.98 on Tuesday. The firm has a market cap of $371.04 million, a P/E ratio of -4.15 and a beta of 3.28. Tectonic Therapeutic has a 12-month low of $15.52 and a 12-month high of $39.53. The stock’s 50 day simple moving average is $25.64 and its 200 day simple moving average is $27.98.

Wall Street Analyst Weigh In

TECX has been the subject of several research reports. Zacks Research raised shares of Tectonic Therapeutic from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tectonic Therapeutic in a report on Thursday, October 15th. UBS Group began coverage on shares of Tectonic Therapeutic in a report on Sunday, October 11th. They issued a “neutral” rating and a $26.00 price objective for the company. TD Cowen reiterated a “buy” rating on shares of Tectonic Therapeutic in a research report on Wednesday, September 30th. Finally, Wells Fargo & Company lowered their target price on shares of Tectonic Therapeutic from $101.00 to $93.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $69.17.

Tectonic Therapeutic Company Profile

Tectonic Therapeutic, Inc is a clinical-stage biotechnology company focused on developing medicines that target G protein-coupled receptors (GPCRs), a large class of cell-surface proteins involved in numerous biological processes and diseases. The company seeks to address GPCRs that have historically been difficult to target with conventional drug-discovery methods.

Tectonic Therapeutic uses its proprietary GEODe platform to identify and develop antibodies and other biologic medicines against GPCRs.